0001213900-26-033808
SEC filingSpectral AI, Inc. (MDAI) reported FY 2025 research and development revenue of $19.6 million, down 33.6% YoY from $29.6 million in 2024, primarily due to reduced activity under the BARDA PBS contract nearing base phase completion. Gross profit was $8.9 million, a 32.8% YoY decline from $13.3 million, with gross margin improving slightly to 45.4% from 44.9% due to higher direct labor allocation. Operating loss widened to $8.6 million from $6.6 million, driven by $17.5 million in G&A expenses, down 11.7% YoY amid lower non-revenue R&D and headcount. Net loss narrowed to $7.6 million from $15.2 million, aided by $1.0 million in other income net, including warrant liability changes. Balance sheet shows $21.4 million total assets, with $15.4 million cash, but $27.1 million liabilities exceed equity by $5.7 million deficit. Operating cash use was $9.9 million, offset by $20.1 million financing inflows, yielding $10.2 million net cash increase. BARDA funding up to $150 million and UK commercialization plans signal growth potential, though regulatory approvals and funding reliance pose risks.
Spectral AI reported FY 2025 R&D revenue of $19.6M, down 33.6% YoY from $29.6M, reflecting PBS BARDA contract progression. Gross profit fell 32.8% to $8.9M (45.4% margin vs 44.9%), operating loss widened to $8.6M from $6.6M on $17.5M G&A (down 11.7%). Net loss improved to $7.6M from $15.2M due to $1.0M other income net. Cash grew to $15.4M via $20.1M financing, despite $9.9M operating outflow. One operating segment focused on DeepView System.
Revenue solely from R&D contracts: BARDA $17.7M (-36.6% YoY), other U.S. gov $2.0M (+16.2%). Decline tied to BARDA base phase end; MTEC/DHA support handheld development. No product revenue; commercialization pending UKCA/FDA approvals targeted 2026.
Gross margin rose to 45.4% from more direct labor on BARDA. Operating margin negative at -43.8% vs -22.3%. G&A down on lower non-revenue R&D/headcount. Non-op items volatile: warrant FV change -$3.2M expense vs prior gain.
Operating cash -$9.9M (vs -$9.2M), financing +$20.1M (Avenue $8.3M, equity $10.6M). Net cash +$10.2M to $15.4M (end period $4.8M? XBRL conflict, use $15.4M). Assets $21.4M, liabilities $27.1M (notes $8.4M, warrants $11.5M), deficit -$5.7M. Liquidity supported by BARDA/MTEC.
BARDA up to $150M (initial $54.9M), MTEC extended to 2026. UK sales 2026 post-UKCA; FDA De Novo June 2025 submission, clearance H1 2026. Focus burn indication, handheld/3D expansions. Risks: funding dependence, regulatory delays, cash burn.